共 33 条
- [21] A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate.ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1234 - S1235Genovese, Mark C.Greenwald, MariaCodding, ChristineCardiel, Mario H.Zubrzycka-Sienkiewicz, AnnaKivitz, Alan J.Wisseh, SteveShay, KathyjoGarg, Jay P.
- [23] EFFICACY AND SAFETY OF ORAL TLR8 AGONIST GS-9688 IN VIRALLY-SUPPRESSED ADULT PATIENTS WITH CHRONIC HEPATITIS B: A PHASE 2, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTI-CENTER STUDYHEPATOLOGY, 2019, 70 : 435A - 436AGane, Edward J.Zhao, YangTan, SusannaLau, Audrey H.Gaggar, AnujSubramanian, ManiKottilil, ShyamTang, Lydia
- [24] Results of a phase 2b multi-center, randomized, double-blind, placebo-controlled study of an RNAi therapeutic, ALN-RSV01, in respiratory syncytial virus (RSV)-infected lung transplant patientsEUROPEAN RESPIRATORY JOURNAL, 2012, 40Simon, AmyGlanville, AllanZamora, MartinHodges, TonyArcasoy, SelimMusk, MichaelSommerwerck, UrteDeVincenzo, JohnKarsten, VerenaShah, ShailyCehelsky, JeffreyNochur, SaraGollob, JaredVaishnaw, AkshayGottlieb, Jens
- [25] SAFETY AND EFFICACY OF 8MG ONCE-DAILY VERSUS 4MG TWICE-DAILY SILODOSIN WITH LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BPH; 12-WEEK, DOUBLE-BLIND, RANDOMIZED, COMPARISON, MULTI-CENTER STUDYNEUROUROLOGY AND URODYNAMICS, 2013, 32 (02) : 161 - 161Song, MihoChun, JiyounHan, Ji-YeonPark, Won HeePaick, Jae-SeungLee, Kyu-SungChoo, Myung-SooKim, Joon ChulChoi, Jong Bo
- [26] A Phase 2a Randomized Placebo-Controlled Double-Blind Multi-Center Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Patients With Moderately Active Ulcerative ColitisGASTROENTEROLOGY, 2010, 138 (05) : S9 - S9Vermeire, SeverineRutgeerts, Paul J.D'Haens, Geert R.De Vos, MartineBressler, BrianVan der Aa, AnnegretCoulie, BernardWong, Cindy J.Feagan, Brian G.
- [27] DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS): 12-WEEK RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDYANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 70 - 70van der Heijde, D.Gensler, L. S.Deodhar, A.Baraliakos, X.Poddubnyy, D.Farmer, M. K.Baeten, D.Kumke, T.Oortgiesen, M.Dougados, M.
- [28] Efficacy and safety of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, for the treatment of moderate-to-severe hidradenitis suppurativa (HS): a 12-week, randomised, double-blind, placebo-controlled, Phase 2 studyEXPERIMENTAL DERMATOLOGY, 2020, 29 : 31 - 32Jemec, Gregor B. E.Sayed, ChristopherSchmieder, GeorgeWeisman, JamieRolleri, RobertSeegobin, SethShaw, StevanGlatt, SophieBaeten, DominiqueIonescu, LucianZouboulis, Christos C.
- [29] A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate.ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S421 - S422Kivitz, Alan J.Zubrzycka-Sienkiewicz, AnnaGutierrez-Urena, Sergio R.Poiley, JeffreyKristy, RitaShay, KathyjoGarg, Jay P.
- [30] Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging studyLANCET, 2024, 404 (10452): : 540 - 553Fisher, Benjamin A.Mariette, XavierPapas, AthenaGrader-Beck, ThomasBootsma, HendrikaNg, Wan-Faivan Daele, P. L. A.Finzel, StephanieNoaiseh, GhaithElgueta, SergioHermann, JosefMcCoy, Sara S.Akpek, EsenBookman, ArthurSopala, MonikaMontecchi-Palmer, MichelaLuo, Wen-LinScheurer, CorneliaHueber, Wolfgang